Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 11630.0
(4.77%)
KRW 11630.0
(4.77%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.58 Billion KRW | -12.16% |
| 2022 | 2.94 Billion KRW | -12.05% |
| 2021 | 3.34 Billion KRW | -20.52% |
| 2020 | 4.21 Billion KRW | -30.68% |
| 2019 | 6.07 Billion KRW | 45.62% |
| 2018 | 4.17 Billion KRW | -28.95% |
| 2017 | 5.87 Billion KRW | -11.82% |
| 2016 | 6.66 Billion KRW | 20.96% |
| 2015 | 5.5 Billion KRW | -19.39% |
| 2014 | 6.83 Billion KRW | -24.98% |
| 2013 | 9.11 Billion KRW | -11.69% |
| 2012 | 10.31 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 689.14 Million KRW | 16.43% |
| 2024 Q1 | 591.92 Million KRW | -77.13% |
| 2023 Q4 | 2.58 Billion KRW | 13.57% |
| 2023 FY | 2.58 Billion KRW | -12.16% |
| 2023 Q1 | 2.73 Billion KRW | -7.31% |
| 2023 Q2 | 2.03 Billion KRW | -25.38% |
| 2023 Q3 | 2.27 Billion KRW | 11.83% |
| 2022 Q4 | 2.94 Billion KRW | 28.02% |
| 2022 Q1 | 2.48 Billion KRW | -25.87% |
| 2022 Q2 | 1.85 Billion KRW | -25.14% |
| 2022 Q3 | 2.3 Billion KRW | 23.8% |
| 2022 FY | 2.94 Billion KRW | -12.05% |
| 2021 Q3 | 4.01 Billion KRW | -5.36% |
| 2021 FY | 3.34 Billion KRW | -20.52% |
| 2021 Q1 | 4.53 Billion KRW | 7.68% |
| 2021 Q2 | 4.24 Billion KRW | -6.45% |
| 2021 Q4 | 3.34 Billion KRW | -16.63% |
| 2020 Q4 | 4.21 Billion KRW | -14.01% |
| 2020 FY | 4.21 Billion KRW | -30.68% |
| 2020 Q2 | 5.36 Billion KRW | -5.79% |
| 2020 Q1 | 5.69 Billion KRW | -6.38% |
| 2020 Q3 | 4.9 Billion KRW | -8.6% |
| 2019 Q3 | 5.18 Billion KRW | 21.73% |
| 2019 FY | 6.07 Billion KRW | 45.62% |
| 2019 Q4 | 6.07 Billion KRW | 17.28% |
| 2019 Q2 | 4.25 Billion KRW | 24.23% |
| 2019 Q1 | 3.42 Billion KRW | -17.89% |
| 2018 Q1 | 6.51 Billion KRW | 10.95% |
| 2018 FY | 4.17 Billion KRW | -28.95% |
| 2018 Q4 | 4.17 Billion KRW | 3.98% |
| 2018 Q3 | 4.01 Billion KRW | -32.14% |
| 2018 Q2 | 5.91 Billion KRW | -9.24% |
| 2017 Q4 | 5.87 Billion KRW | -37.57% |
| 2017 FY | 5.87 Billion KRW | -11.82% |
| 2017 Q1 | 7.44 Billion KRW | 11.68% |
| 2017 Q2 | 7.46 Billion KRW | 0.29% |
| 2017 Q3 | 9.41 Billion KRW | 26.1% |
| 2016 FY | 6.66 Billion KRW | 20.96% |
| 2016 Q2 | 5.63 Billion KRW | 7.69% |
| 2016 Q3 | 8.29 Billion KRW | 47.13% |
| 2016 Q4 | 6.66 Billion KRW | -19.65% |
| 2016 Q1 | 5.23 Billion KRW | -4.99% |
| 2015 Q3 | 5.02 Billion KRW | 4.19% |
| 2015 Q4 | 5.5 Billion KRW | 9.7% |
| 2015 Q2 | 4.82 Billion KRW | -32.13% |
| 2015 Q1 | 7.1 Billion KRW | 3.92% |
| 2015 FY | 5.5 Billion KRW | -19.39% |
| 2014 Q2 | 5.29 Billion KRW | -22.22% |
| 2014 Q3 | 4.95 Billion KRW | -6.51% |
| 2014 Q1 | 6.81 Billion KRW | -25.22% |
| 2014 Q4 | 6.83 Billion KRW | 37.94% |
| 2014 FY | 6.83 Billion KRW | -24.98% |
| 2013 FY | 9.11 Billion KRW | -11.69% |
| 2013 Q1 | 9.81 Billion KRW | -4.86% |
| 2013 Q2 | 10.08 Billion KRW | 2.77% |
| 2013 Q4 | 9.11 Billion KRW | -4.06% |
| 2013 Q3 | 9.49 Billion KRW | -5.87% |
| 2012 FY | 10.31 Billion KRW | 0.0% |
| 2012 Q4 | 10.31 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 35.26 Billion KRW | 92.66% |
| ST Pharm Co.,Ltd. | 120.73 Billion KRW | 97.856% |
| ABL Bio Inc. | - KRW | -Infinity% |
| Cellid, Co., Ltd. | - KRW | -Infinity% |